EV Biologics, Inc. (YECO)
OTCMKTS · Delayed Price · Currency is USD
0.0808
0.00 (0.00%)
At close: Jul 16, 2025
EV Biologics Revenue
In the year 2017, EV Biologics had annual revenue of $9.47M, down -0.34%. EV Biologics had revenue of $2.46M in the quarter ending June 30, 2017, a decrease of -78.05%.
Revenue
9.47M
Revenue Growth
-70.48%
P/S Ratio
0.09
Revenue / Employee
n/a
Employees
n/a
Market Cap
826.21K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2017 | 9.47M | -32.45K | -0.34% |
Jun 30, 2017 | 9.51M | -33.14M | -77.71% |
Jun 30, 2016 | 42.64M | -3.59M | -7.76% |
Jun 30, 2015 | 46.23M | 1.77M | 3.99% |
Jun 30, 2014 | 44.46M | 1.98M | 4.65% |
Jun 30, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
EV Biologics News
- 1 year ago - EV Biologics Updates on Funding and Sales - Accesswire
- 2 years ago - EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic - Accesswire
- 2 years ago - EV Biologics Appoints Senior Investment Banker as Corporate Finance Director - Accesswire
- 2 years ago - EV Biologics Hires Senior Chief Financial Officer - Accesswire
- 2 years ago - EV Biologics Signs Exclusive Distribution Agreement for South America - Accesswire
- 2 years ago - EV Biologics Generates Mesenchymal Stem Cell Lines - Accesswire
- 2 years ago - EV Biologics Updates on Excyte Subsidiary Funding - Accesswire
- 2 years ago - EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX - Accesswire